 Commercial launch of BentrioTM nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 Enrollment in Phase 2 trial of AM-125 for acute vertigo reached its midpoint in May 2021 and completion is expected in the autumn of 2021 Transformative acquisition of Trasir Therapeutics completed and strategic repositioning around RNA therapeutics well underway HAMILTON, BERMUDA ACCESSWIRE September 8, 2021 Altamira Therapeutics Ltd. NASDAQ:CYTO Altamira or the Company, a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update and announced first half 2021 financial results. 